Mast cell disease in children is strictly cutaneous in 90%
of cases, with the remaining 10% having systemic disease. In cutaneous disease, urticaria pigmentosa is
found about 80% of the time; mastocytoma, 11%; diffuse cutaneous mastocytosis,
9%. Prognosis for children with these
diseases is generally good. Pediatric
mast cell disease usually improves markedly or resolves completely before
puberty.
In 85% of patients, skin lesions formed before the age of
2. Diffuse cutaneous mastocytosis is
found exclusively in children less than a year old. In 13% of cases, another family member also
had mastocytosis.
Disease was benign in 80% of children. All children with systemic mastocytosis
presented initially with this disease and did not progress from another
diagnosis. There is no known disease
course in which children progress from indolent SM to more aggressive disease. 15-30% cases of childhood SM continue into
adulthood, with the rest resolving fully.
As in adults, symptoms vary greatly. Systemic symptoms are often seen in children
with cutaneous disease, although not with solitary mastocytomas. The most common symptoms are itching,
flushing, blisters and GI symptoms. Children
with severe, blistering rashes are at highest risk for anaphylaxis.
Children are diagnosed in much the same way as adults, with
biopsy of lesions and testing for markers, including receptors seen on
neoplastic mast cells, the D816V CKIT mutation and serum tryptase levels. Treatment is also similar, with
antihistamines, leukotriene antogonists, mast cell stabilizers and topical
steroids. Chemotherapy is not indicated
in cutaneous disease or indolent SM.
In cutaneous disease, mutations were found in codon 816 (the
location of the CKIT gene) 42% of the time, with mutations outside of this
outside found 44% of the time.
Furthermore, many of these mutations affected the CKIT receptor differently
than in adults. This finding reinforces
the idea that childhood mastocytosis is different from adult mastocytosis.
No comments:
Post a Comment